ArticleWorld journal of clinical oncology2011
Lentinan prolonged survival in patients with gastric cancer receiving S-1-based chemotherapy.
Article in World journal of clinical oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Efficacy of biological response modifier lentinan with chemotherapy for advanced cancer: a meta-analysis.Cancer medicine · 2017Pooled it
- Therapeutic effects of Lentinan in gastrointestinal inflammation and carcinogenesis - A scoping review of evidence from preclinical and clinical studies.European journal of microbiology & immunology · 2026Review
- Neutrophil efferocytosis in chronic inflammatory gastrointestinal diseases: mechanistic insights and therapeutic potential.Frontiers in immunology · 2026Review
- Research advances in fungal polysaccharides: production, extraction, characterization, properties, and their multifaceted applications.Frontiers in cellular and infection microbiology · 2025Review
- Theranostic Cancer Treatment Using Lentinan-Coated Selenium Nanoparticles and Label-Free CEST MRI.Pharmaceutics · 2022Article
- Synthesis of bioactive (1→6)-β-glucose branched poly-amido-saccharides that stimulate and induce M1 polarization in macrophages.Nature communications · 2022Article
- How Should the Worldwide Knowledge of Traditional Cancer Healing Be Integrated with Herbs and Mushrooms into Modern Molecular Pharmacology?Pharmaceuticals (Basel, Switzerland) · 2022Review
- Immunoregulatory activity of a low-molecular-weight heteropolysaccharide fromFood chemistry: X · 2022Article
- Intramolecular displacement reactions involving sulfur leading to the formation of 3,6-thiaanhydro sugar derivatives during the synthesis of 3,5-dithio-glucofuranose.European journal of organic chemistry · 2022Article
- Review
- Combining the Anticancer and Immunomodulatory Effects ofNutrients · 2021Article
- Edible Mushrooms and Beta-Glucans: Impact on Human Health.Nutrients · 2021Review
- Medicinal Mushrooms: Bioactive Compounds, Use, and Clinical Trials.International journal of molecular sciences · 2021Review
- Glucan and Mannan-Two Peas in a Pod.International journal of molecular sciences · 2019Review
- Synthesis and Evaluation of 1,5-Dithia-d-laminaribiose, Triose, and Tetraose as Truncated β-(1→3)-Glucan Mimetics.The Journal of organic chemistry · 2018Article
- Lentinan as an immunotherapeutic for treating lung cancer: a review of 12 years clinical studies in China.Journal of cancer research and clinical oncology · 2018Review
- Fraction From Lycium barbarum Polysaccharides Reduces Immunotoxicity and Enhances Antitumor Activity of Doxorubicin in Mice.Integrative cancer therapies · 2018Article
- Beta-glucan contamination of pharmaceutical products: How much should we accept?Cancer immunology, immunotherapy : CII · 2016Review
- Chemo-Immunotherapy Using Lentinan for the Treatment of Gastric Cancer with Liver Metastases.Medical sciences (Basel, Switzerland) · 2016Article
- Effect of Beta glucan on quality of life in women with breast cancer undergoing chemotherapy: a randomized double-blind placebo-controlled clinical trial.Advanced pharmaceutical bulletin · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo examine whether administration of lentinan, purified β-1, 3-glucan, can prolong survival in advanced gastric cancer patients receiving S-1-based chemotherapy.
methodsSince 2004, 78 patients with metastatic or recurrent gastric cancer have received S-1-based chemotherapy as first-line treatment. Survival, side effects, and the ratio of granulocytes/lymphocytes (G/L ratio) were compared between 2 groups of patients who received chemo-immunotherapy using lentinan and chemotherapy alone.
resultsMedian overall survival was significantly longer in the former group than in the latter group [689 d (95% CI: 431-2339 d) vs 565 d (95% CI: 323-662 d), P = 0.0406]. In addition, the G/L ratio in patients who received lentinan was maintained around or below 2, which was significantly lower than that in patients who received chemotherapy alone (P < 0.001).
conclusionChemo-immunotherapy with lentinan offers a significant advantage over S-1-based chemotherapy alone in terms of survival in patients with advanced gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.